Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
November 30, 2022 16:15 ET
|
Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 06:59 ET
|
Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
August 25, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of...
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
August 23, 2022 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
July 12, 2022 07:00 ET
|
Synlogic, Inc.
Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
June 21, 2022 07:00 ET
|
Synlogic, Inc.
BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
December 15, 2021 07:00 ET
|
Travere Therapeutics, Inc.
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
November 16, 2020 08:00 ET
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...